Search

Your search keyword '"Fowler, Nathan"' showing total 1,356 results

Search Constraints

Start Over You searched for: Author "Fowler, Nathan" Remove constraint Author: "Fowler, Nathan"
1,356 results on '"Fowler, Nathan"'

Search Results

2. Procrustes is a machine-learning approach that removes cross-platform batch effects from clinical RNA sequencing data

3. Safety and activity of lenalidomide in combination with obinutuzumab in patients with relapsed indolent non-Hodgkin lymphoma: a single group, open-label, phase 1/2 trial

4. Comprehensive peripheral blood immunoprofiling reveals five immunotypes with immunotherapy response characteristics in patients with cancer

6. Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update

7. Multi-omic profiling of follicular lymphoma reveals changes in tissue architecture and enhanced stromal remodeling in high-risk patients

11. Integrated genomic and transcriptomic characterization of neuroendocrine carcinomas for improved treatment decision-making.

13. Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma

14. Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma

16. STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial

17. Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphoma

18. SIRPα+ macrophages are increased in patients with FL who progress or relapse after frontline lenalidomide and rituximab

19. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial

20. Autologous stem cell transplantation for large B-cell lymphoma with secondary central nervous system involvement

21. Ibrutinib–rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial

23. Gastric Cancer Tumor Immune Microenvironment Landscape: Clinical Implications for Patient Outcome and Response to PD-1 Immune Checkpoint Blockade

24. Clinical Outcomes of Patients with Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 Elara 3-Year Follow-up

25. Long-Term Durable Responses in Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL), Diffuse Large B-Cell Lymphoma (DLBCL), and Follicular Lymphoma (FL) Treated with Tisagenlecleucel and Its Association with Persistence of Chimeric Antigen Receptor (CAR) T Cells

28. Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma

29. Integrative genomic analysis identifies unique immune environments associated with immunotherapy response in diffuse large B cell lymphoma

31. Role of the tumor microenvironment in mature B-cell lymphoid malignancies

32. Test-the-Test: Clinical Utility of Comprehensive Whole Exome Sequencing and RNA-Seq for Patients with Lymphoma

33. Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study

34. 555 Challenges in predicting ICI response in HPV+ HNSCC: insights into the tumor microenvironment

35. Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas

37. CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma

40. Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma

44. Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial

45. Hitting a Moving Target: Successful Management of Diffuse Large B-cell Lymphoma Involving the Mesentery With Volumetric Image-guided Intensity Modulated Radiation Therapy

46. POSTER: CT-564 ELARA Trial Update: Long-Term Clinical Outcomes and Correlative Efficacy Analyses of Tisagenlecleucel in Patients With Relapsed/Refractory Follicular Lymphoma (R/R FL)

47. CT-564 ELARA Trial Update: Long-Term Clinical Outcomes and Correlative Efficacy Analyses of Tisagenlecleucel in Patients With Relapsed/Refractory Follicular Lymphoma (R/R FL)

48. CD8 T-cell dysfunction is linked with CAR T-cell failure and can be mitigated by a non-alpha IL-2 agonist, pegenzileukin

49. P1205: A LIVING PATIENT-DERIVED BIOREPOSITORY FOSTERING MICROENVIRONMENT DISSECTION IN T-CELL LYMPHOMA

50. Prolonged cytopenia following CD19 CAR T cell therapy is linked with bone marrow infiltration of clonally expanded IFNγ-expressing CD8 T cells

Catalog

Books, media, physical & digital resources